C-terminal protein amino acid modification

Across TCGA cell cohorts, RNA activity of the C-terminal protein amino acid modification pathway is significantly associated with the drug response of multiple features, with the CNS cohort showing a particularly strong set of associations.

The most reproducible pathway-associated features across cancer lineages are Niraparib, FGFR_0939, and WEHI-539, each associated with the pathway in up to 2 cancer types. Since the analysis shows associations rather than directional relationships, both pathway-to-partner and partner-to-pathway views are reported.

Each partner is linked to its corresponding Q-omics profile. The box plot shows the strongest association, Niraparib grouped by C-terminal protein amino acid modification-low versus -high activity in CNS.

Pathway-associated features by consensus

Ranked by combined sampling and lineage consensus. X-score (pathway→partner) and Y-score (partner→pathway) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner feature	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
CNS	Niraparib →	+0.874	+0.267	.009	.016	3	1
CNS	FGFR_0939 →	-0.705	-0.370	.045	.021	2	2
CNS	WEHI-539 →	+0.504	+0.370	.003	.021	3	1
CNS	Vinorelbine →	-0.717	-0.370	.002	.021	3	1
CNS	Docetaxel →	-0.575	-0.370	.031	.021	2	1
CNS	Alisertib →	-0.677	-0.370	.015	.021	2	1

Each partner links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Niraparib by C-terminal protein amino acid modification activity — CNS

Explore this box plot interactively →